The Reliability of Histoculture Drug Response Assay (HDRA) in Chemosensitivity Tests for Breast Cancer.
- Author:
Hee Joon KANG
1
;
Chang Dae KO
;
Ho Sung YOON
;
Moon Bo KIM
;
Sei Hyun AHN
Author Information
1. Department of Surgery, Ulsan University College of Medicine, Korea. ahnsh@amc. seoul.kr
- Publication Type:Clinical Trial ; In Vitro ; Original Article
- Keywords:
Breast neoplasm;
Chemosensitivity test
- MeSH:
Breast Neoplasms*;
Breast*;
Cell Culture Techniques;
Drug Therapy;
Humans
- From:Cancer Research and Treatment
2001;33(5):392-397
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Cancers are highly individual in their response to chemotherapy, however attempts to predict tumor response to drugs using in vitro cell culture have largely failed. A new technology, the histoculture drug response assay (HDRA), appears to have solved many previous problems. The purpose of this study is to evaluate the reliability of HDRA in a chemosensitivity test for breast cancer. MATERIALS AND METHODS: Tumor specimens from breast cancer patients were evaluated by HDRA using different chemotherapeutic agents. Each specimen was tested using a blind method in order to determine the reproducibility of HDRA results for the same tissue and with a triplicated assay in order to determine reproducibility by different examiners. The evaluative power of this assay and the chemosensitivity of drugs for each specimen was determined. RESULTS: Specimens of 92.9% (65/70) were successfully cultured and evaluated for chemosensitivity. The reproducibility of HDRA for the same tissue was 75% (100% agreement) and 100% (over 70% agreement), respectively. And the reproducibility by different examiners was 78.9% (100% agreement) and 94.7% (over 70% agreement), respectively. Each specimen demonstrated a response to at least one agent. CONCLUSION: The evaluative power and reproducibility of HDRA were high, therefore it might serve as a reliable clinical method for chemosensitivity testing. However, there is a need for clinical trial in which patients are initially randomized for treatment either by HDRA direction or by clinician's choice.
